Fact CheckerSign in

NCT05144776Completed

Evaluation of Hepatitis B Virus (HBV) DNA Test As Point of Care Tool

Evaluation of Novel Hepatitis B DNA Test from Capillary Blood At the Point-of-care As a Tool to Enhance Clinical Management

Source: ClinicalTrials.gov · Last updated 6 Mar 2025

Brief summary (registry, in English)

This is a cross sectional observational study to asses the performance of two novel HBV DNA testing methodologies; a) dried blood spot sampling and b) fingerstick capillary blood using the Xpert® Hepatitis B Virus viral load assay. Both novel testing methodologies will be compared with venous blood tested using a gold standard HBV DNA assay. The sensitivity and specificity of the two novel testing will be evaluated. HBV viral load tests are essential to guide antiviral treatment eligibility and effectiveness. However, many people are unable to access these tests, particularly those living in remote or limited resources settings given high cost, or unavailable infrastructure. Simple, affordable and accessible HBV viral load tests are required to increase global access to HBV testing and treatment to meet the WHO HBV elimination targets. The GeneXpert Diagnostic Systems, the most common molecular point-of-care platform globally, has the potential to provide simple and affordable HBV viral load tests. Dried Blood Spot testing is also an affordable and accessible testing methodology particularly suited to remote and resource limited settings. This proof-of-concept study will assess the feasibility and diagnostic performance of Xpert® HBV Viral Load test and Dried Blood Spot testing for the quantitation of HBV DNA from fingerstick capillary samples.

Status (registry)
Completed
Study type
Observational
Enrollment
268 (actual)
First submitted
22 Nov 2021
Start date
17 Nov 2022
Primary completion date
1 Jun 2024
Lead sponsor
Kirby Institute
Diseases
Hepatitis B
NCT number
NCT05144776

What you commit to

  • Study type: Observational
  • Participants enrolled: 268
  • From 17 Nov 2022 to the primary completion date, 1 Jun 2024
  • 6 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Nil

Who the study is looking for

  • Have voluntarily signed the informed consent form, 18 years of age or older, HBsAg positive

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (6)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
St Vincent's Hospital Melbourne
Coordinator of this site? Confirm its status
MelbourneAustraliaUnknown status
STORR Liver Centre Westmead Hospital
Coordinator of this site? Confirm its status
SydneyAustraliaUnknown status
Blacktown Hospital
Coordinator of this site? Confirm its status
SydneyAustraliaUnknown status
St Vincent's Hospital
Coordinator of this site? Confirm its status
SydneyAustraliaUnknown status
Prince of Wales Hospital
Coordinator of this site? Confirm its status
SydneyAustraliaUnknown status
Liverpool Hospital
Coordinator of this site? Confirm its status
SydneyAustraliaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.